ARS Pharmaceuticals announces FDA acceptance of NDA for neffy ® (epinephrine nasal spray) for the Treatment of Allergic Reactions (type I) including Anaphylaxis

neffy has potential to be the first non-injectable medicine indicated to treat allergic reactions (type I) including anaphylaxis in the U.S., if approved SAN DIEGO– October 21, 2022– ARS Pharmaceuticals, Inc. announced today that...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials